Objective: To compare the effects of a 12-week treatment with 17ss-estradiol given alone and in sequential combination with 3.75 mg of nomegestrol acetate (Naemis), or a placebo on biochemical markers of bone turnover in menopausal women.
Patients And Methods: A double-blind, randomized, placebo and estradiol-controlled multicenter study was conducted. A total of 176 patients who had been menopausal for 1-10 years, hysterectomized or not, having no contraindications to hormone replacement therapy, without any risks factors for osteoporosis, received one of these treatments during 12 weeks: placebo, 1.5 mg estradiol (E(2)) or 1.5 mg E(2)/3.75 mg nomegestrol acetate (E(2)/NOMAC). The primary efficacy variables were the change in bone markers (total alkaline phosphatase, bone alkaline phosphatase and osteocalcin; urinary type-I collagen peptides).
Results: The four biochemical markers decreased only in the E(2)/NOMAC group. Bone alkaline phosphatase, osteocalcin and urinary type-I collagen peptides decreased in the E(2) group. For both active treatment groups compared to the placebo group, the changes were statistically significant after a 12-week treatment. There were no statistically significant differences between the E(2) and the E(2)/NOMAC groups except for total serum alkaline phosphatase, whose mean value decreased in the E(2)/NOMAC group but increased slightly in the E(2) group (p < 0.001). Furthermore, after a 6-week treatment, the changes in biochemical markers of bone turnover were similar to those found after 12 weeks. Safety data were satisfactory with regard to estradiol given alone or in combination with nomegestrol acetate.
Conclusion: These results demonstrated that 1.5 mg E(2) is effective in reducing bone turnover in postmenopausal women and proved that the combination of 1.5 mg E(2) and 3.75 mg nomegestrol acetate has no deleterious effect on bone remodelling.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13697130500103433 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Petroclival meningioma regression after combined oestrogen and nomegestrol acetate interruption.
BMJ Case Rep
January 2025
Neurosurgery, CHU de Liege Hospital Sart Tilman, Liege, Belgium
Meningioma regression after progestin treatment interruption is already established. Zoely is a combined oral contraceptive including oestradiol and progestin (nomegestrol acetate). The effect of combined oestrogen with nomegestrol acetate on meningioma is currently unknown.
View Article and Find Full Text PDFImpact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data.
Contraception
December 2024
LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany; Center for Translational Neuro and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany; Bielefeld University, Medical School and University Medical Center OWL, Protestant Hospital of the Bethel Foundation, Department of Psychiatry and Psychotherapy, Bielefeld, Germany.
Objectives: To assess the risk of contraceptive failure and adverse events (AEs) associated with the type of progestin when coadministered with psychotropic drugs within a routine clinical practice setting.
Study Design: A pooled analysis of four large, prospective, multinational cohort studies including women with a new prescription of combined oral contraceptives (COCs) and concomitant psychotropic drug use from 13 European countries and the United States. We determined the frequency of contraceptive failures and AEs within 6 months after COC initiation by progestin type.
Comparative study on the effects of combined oral contraceptives and dienogest in women with endometriosis‑associated chronic pelvic pain.
Eur J Obstet Gynecol Reprod Biol
January 2025
Department of General Surgery and Medical-Surgical Specialties, Gynaecological Clinic, School of Medicine, University of Catania, Catania, Italy.
Article Synopsis
- The study aimed to compare the pain relief effects of five different combined oral contraceptives (COCs) in women suffering from endometriosis-related chronic pelvic pain, dysmenorrhea, and dyspareunia.
- Conducted between October 2018 and March 2023, the research involved tracking pain levels using a visual analogue scale over 6 months across multiple treatment groups.
- Results indicated that COCs with estradiol (E2) or estetrol (E4) led to significantly better pain relief compared to those with ethinylestradiol (EE), and E2 or E4-containing COCs may be preferable alternatives to dienogest (DNG) for women preferring birth control.
The use of oral nomegestrol acetate/estradiol in rapid and random start preparation of endometrium before office hysteroscopic polypectomies: A multicenter, prospective, randomized controlled trial.
Eur J Obstet Gynecol Reprod Biol
August 2024
Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy.
Objective: To evaluate the use of oral nomegestrol acetate/estradiol in random start rapid preparation of endometrium before office hysteroscopic polypectomy.
Study Design: Multicenter, prospective, randomized controlled trial.
Setting: University hospitals.
Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study.
Lancet Reg Health Eur
July 2024
EPI-PHARE Scientific Interest Group (French National Agency for the Safety of Medicines and Health Products, and French National Health Insurance), Saint-Denis, France.
Background: Nomegestrol acetate (NOMAC) is a synthetic potent progestogen. This study aimed to assess the risk of intracranial meningioma associated with the prolonged use of NOMAC.
Methods: Observational cohort study using SNDS data (France).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!